Overview

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.
Phase:
Phase 2
Details
Lead Sponsor:
Conatus Pharmaceuticals Inc.